Claims for Patent: 10,004,792

Summary for Patent: 10,004,792

Title:	Peptides and combination of peptides for use in immunotherapy against various cancers
Abstract:	The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
Inventor(s):	Mahr; Andrea (Tuebingen, DE), Weinschenk; Toni (Aichwald, DE), Song; Colette (Ostfildern, DE), Schoor; Oliver (Tuebingen, DE), Fritsche; Jens (Dusslingen, DE), Singh; Harpreet (Houston, TX)
Assignee:	IMMATICS BIOTECHNOLOGIES GMBH (Tuebingen, DE)
Application Number:	15/374,993
Patent Claims:	1. A method of eliciting an immune response in a patient who has cancer, comprising administering to the patient a population of activated T cells that selectively recognize cancer cells that present a peptide consisting of the amino acid sequence of SLFPDSLIV (SEQ ID NO: 64), wherein the activated T cells are produced by contacting T cells with the peptide loaded human class I or II MEW molecules expressed on the surface of an antigen-presenting cell for a period of time sufficient to activate the T cells, wherein said cancer is selected from the group consisting of glioblastoma, breast cancer, colorectal cancer, renal cell carcinoma, chronic lymphocytic leukemia, hepatocellular carcinoma, non-small cell and small cell lung cancer, Non-Hodgkin lymphoma, acute myeloid leukemia, ovarian cancer, pancreatic cancer, prostate cancer, esophageal cancer including cancer of the gastric-esophageal junction, gallbladder cancer and cholangiocarcinoma, melanoma, gastric cancer, testis cancer, urinary bladder cancer, head and neck squamous cell carcinoma, and uterine cancer. 2. The method of claim 1, wherein the T cells are autologous to the patient. 3. The method of claim 1, wherein the T cells are obtained from a healthy donor. 4. The method of claim 1, wherein the T cells are obtained from tumor infiltrating lymphocytes or peripheral blood mononuclear cells. 5. The method of claim 1, wherein the activated T cells are expanded in vitro. 6. The method of claim 1, wherein the peptide is in a complex with the class I MEW molecule. 7. The method of claim 1, wherein the antigen presenting cell is infected with recombinant virus expressing the peptide. 8. The method of claim 7, wherein the antigen presenting cell is a dendritic cell or a macrophage. 9. The method of claim 5, wherein the expansion is in the presence of an anti-CD28 antibody and IL-12. 10. The method of claim 1, wherein the population of activated T cells comprises CD8-positive cells. 11. The method of claim 1, wherein the contacting is in vitro. 12. The method of claim 1, wherein the population of activated T cells are administered in the form of a composition. 13. The method of claim 12, wherein the composition comprises an adjuvant. 14. The method of claim 13, wherein the adjuvant is selected from the group consisting of imiquimod, resiguimod, GM-CSF, cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, and particulate formations with poly(lactid co-glycolid) (PLG) and virosomes. 15. The method of claim 1, wherein the immune response is capable of killing cancer cells that present a peptide consisting of the amino acid sequence of SLFPDSLIV (SEQ ID NO: 64). 16. The method of claim 1, wherein the immune response comprises a cytotoxic T cell response. 17. The method of claim 1, wherein the cancer is prostate cancer. 18. The method of claim 1, wherein the cancer is non-small cell and small cell lung cancer.

Details for Patent 10,004,792

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	February 26, 2004		2035-12-11